Related Experiment Video
Updated: Aug 21, 2026

Design of Cecal Ligation and Puncture and Intranasal Infection Dual Model of Sepsis-Induced Immunosuppression
Published on: June 15, 2019
Advances in Sepsis Treatment
Abstract:
Investigations of novel sepsis treatments have proven ineffective in the past. Despite advances in overall care of critically ill patients, therapies specifically designated for sepsis were lacking. However, research unveiled a complex interaction between the coagulation and inflammation systems, which has served as an impetus for innovative pharmacologic therapies in the treatment of patients with sepsis. This article summarizes the results of trials involving drotrecogin alfa (activated), or recombinant human activated protein C, the only medicine currently approved by the US Food and Drug Administration for the treatment of severe sepsis. In addition, the beneficial effects of early, goal-directed resuscitation, guided by continuous central venous oxygen saturations, are discussed, with the issues involved in the use of corticosteroids in a subset of patients with septic shock. This article also reviews the beneficial effects of tight glycemic control in postoperative critically ill patients and considers whether the data can be extrapolated to medical patients.
Insights
New pharmacologic therapies targeting sepsis, including drotrecogin alfa (activated), show promise. Early goal-directed resuscitation and tight glycemic control are also discussed for severe sepsis and septic shock management.
Area of Science:
- Critical Care Medicine
- Pharmacology
- Intensive Care
Background:
- Sepsis treatment has historically lacked targeted therapies despite advances in critical care.
- A complex interplay between coagulation and inflammation systems has spurred novel pharmacologic approaches for sepsis.
Purpose of the Study:
- To review innovative pharmacologic therapies for severe sepsis.
- To discuss early goal-directed resuscitation and corticosteroid use in septic shock.
- To evaluate glycemic control in critically ill patients.
Main Methods:
- Summary of clinical trials involving drotrecogin alfa (activated) (recombinant human activated protein C).
- Discussion of early, goal-directed resuscitation guided by central venous oxygen saturations.
- Review of corticosteroid use in septic shock and glycemic control in postoperative patients.
Main Results:
- Drotrecogin alfa (activated) is the only FDA-approved medicine for severe sepsis.
- Early goal-directed resuscitation demonstrates beneficial effects.
- Tight glycemic control shows benefits in postoperative critically ill patients.
Conclusions:
- Drotrecogin alfa (activated) represents a significant advancement in severe sepsis treatment.
- Early resuscitation strategies and glycemic control are crucial in managing critically ill patients.
- Further research is needed to extrapolate glycemic control data to medical patients.
Related Concept Videos
Acute Pyelonephritis II: Diagnostic Studies and Management
Asepsis
Urine Studies II: Urine Culture and Sensitivity Test
